Wave life sciences reports second quarter 2025 financial results and provides business update

Wve-006, the leading galnac-rna editing oligonucleotide designed to correct aat protein and address both lung and liver manifestations of aatd, rapidly advancing in restoraation-2 study of aatd patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)
WVE Ratings Summary
WVE Quant Ranking